Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
Authors
Keywords
-
Journal
Lancet Haematology
Volume 8, Issue 11, Pages e808-e817
Publisher
Elsevier BV
Online
2021-10-10
DOI
10.1016/s2352-3026(21)00271-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
- (2021) Stephen M Ansell et al. CLINICAL CANCER RESEARCH
- Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
- (2019) Daniela Pende et al. Frontiers in Immunology
- Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
- (2019) Shaheer Khan et al. Frontiers in Oncology
- Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
- (2019) Junhun Cho et al. MODERN PATHOLOGY
- Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
- (2017) Meng Michelle Xu et al. IMMUNITY
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma
- (2015) Elise A. Olsen DERMATOLOGIC CLINICS
- TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL
- (2015) Ilan R. Kirsch et al. Science Translational Medicine
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
- (2013) W. W. Pang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
- (2012) Mark P Chao et al. CURRENT OPINION IN IMMUNOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Topical Chemotherapy in Cutaneous T-cell Lymphoma
- (2012) Stuart R. Lessin et al. JAMA Dermatology
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
- (2011) M. P. Chao et al. BLOOD
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
- (2011) Elise A. Olsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients
- (2010) M. Nagahara et al. CLINICAL CANCER RESEARCH
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
- (2009) P. T. Bradford et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now